ozempic vs tirzepatide Why You Might Tolerate One Weight Loss Drug Better Than Another Ozempic, other GLP-1 weight loss

On March 5, Novo Nordisk released the top-line results from this pivotal kidney outcomes trial: Use of semaglutide in patients with diabetic kidney disease reduced the primary outcomea composite of kidney failure, 50% decline in estimated glomerular filtration rate (eGFR), and cardiovascular (CV) or kidney deathby an impressive 24% (Figure 1)

Peptide therapy is generally well-tolerated when administered under professional supervision

As of 2023, no GLP-1 patches are approved or available for clinical use in the UK or elsewhere

CagriSema combines semaglutide with cagrilintide (an amylin receptor agonist), targeting yet another hormone pathway involved in appetite regulation